How have KIDS shares performed this year?

OrthoPediatrics' stock was trading at $32.51 at the start of the year. Since then, KIDS stock has decreased by 5.7% and is now trading at $30.66. View the best growth stocks for 2024 here .

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) released its quarterly earnings data on Monday, August, 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.08. The business had revenue of $52.80 million for the quarter, compared to analyst estimates of $52.40 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.44% and a negative net margin of 14.35%.

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com . Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did OrthoPediatrics IPO?

OrthoPediatrics (KIDS) raised $52 million in an IPO on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

Who are OrthoPediatrics' major shareholders?

OrthoPediatrics' top institutional investors include Dimensional Fund Advisors LP (1.97%), Paradigm Capital Management Inc. NY (0.56%), Commonwealth Equity Services LLC (0.31%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include David R Bailey, Mark C Throdahl , Fred Hite , Gregory A Odle , Daniel J Gerritzen, Joseph W Hauser, Terry D Schlotterback , Harold Ruf, (Reynolds) Marie C Infante and Jennifer N Pritzker . View institutional ownership trends .

How do I buy shares of OrthoPediatrics?

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OrthoPediatrics investors own include AbbVie (ABBV) , Freeport-McMoRan (FCX) , Gilead Sciences (GILD) , Intel (INTC) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO) .

NASDAQ:KIDS

OrthoPediatrics (KIDS) Stock Price, News & Analysis

$30.66

+0.78 (+2.61%)

(As of 09/6/2024 ET)

Compare

Today's Range: $29.70
▼
$30.86
50-Day Range: $25.33
▼
$35.39
52-Week Range: $23.10
▼
$36.97

Volume: 124,095 shs
Average Volume: 169,473 shs
Market Capitalization: $730.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.50

Get OrthoPediatrics alerts:

OrthoPediatrics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 41.9% Upside
$43.50 Price Target
Short Interest: Bearish
5.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.20
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$293,000 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.96) to ($1.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

Medical Sector

247th out of 910 stocks

Surgical & Medical Instruments Industry

33rd out of 95 stocks

3.4

Analyst's Opinion

Consensus Rating
OrthoPediatrics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
OrthoPediatrics has only been the subject of 2 research reports in the past 90 days.
Read more about OrthoPediatrics' stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
5.42% of the float of OrthoPediatrics has been sold short.
Short Interest Ratio / Days to Cover
OrthoPediatrics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in OrthoPediatrics has recently increased by 2.98%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
OrthoPediatrics does not currently pay a dividend.
Dividend Growth
OrthoPediatrics does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OrthoPediatrics has received a 52.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Cervical implants", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for OrthoPediatrics is -1.20.

1.1

News and Social Media Coverage

News Sentiment
OrthoPediatrics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for OrthoPediatrics this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for KIDS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added OrthoPediatrics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OrthoPediatrics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $293,000.00 in company stock.
Percentage Held by Insiders
31.80% of the stock of OrthoPediatrics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.05% of the stock of OrthoPediatrics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about OrthoPediatrics' insider trading history.

0.0

Earnings and Valuation

Earnings Growth
Earnings for OrthoPediatrics are expected to decrease in the coming year, from ($0.96) to ($1.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OrthoPediatrics is -31.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OrthoPediatrics is -31.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OrthoPediatrics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
Read more about OrthoPediatrics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

⭕ [URGENT] Buy Alert just triggered

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

About OrthoPediatrics Stock (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

KIDS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KIDS Stock News Headlines

August 23, 2024 | insidertrades.com

Daniel J. Gerritzen Sells 10,000 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) Stock

August 28, 2024 | americanbankingnews.com

Insider Selling: OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Sells $293,000.00 in Stock

September 7, 2024 | Weiss Ratings (Ad)

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

August 20, 2024 | globenewswire.com

OrthoPediatrics Corp. to Host Investor Day on September 12, 2024

August 6, 2024 | markets.businessinsider.com

OrthoPediatrics Outperforms with Strong Growth and Strategic Expansion: A Buy Rating Insight

August 5, 2024 | globenewswire.com

OrthoPediatrics Corp. Reports Second Quarter 2024 Financial Results and Reaffirms Full Year 2024 Revenue Guidance

August 5, 2024 | globenewswire.com

OrthoPediatrics Corp. Announces Private Financing

July 28, 2024 | finance.yahoo.com

OrthoPediatrics (NASDAQ:KIDS) shareholders have endured a 48% loss from investing in the stock three years ago

September 7, 2024 | Weiss Ratings (Ad)

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

July 22, 2024 | globenewswire.com

OrthoPediatrics Corp. to Report Second Quarter 2024 Financial Results on August 6, 2024

June 4, 2024 | globenewswire.com

OrthoPediatrics Corp. to Participate in the Truist Securities MedTech Conference

May 15, 2024 | globenewswire.com

OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting

May 8, 2024 | finance.yahoo.com

OrthoPediatrics Corp. (NASDAQ:KIDS) Q1 2024 Earnings Call Transcript

May 8, 2024 | finance.yahoo.com

OrthoPediatrics Corp (KIDS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...

May 8, 2024 | finance.yahoo.com

OrthoPediatrics First Quarter 2024 Earnings: Beats Expectations

May 7, 2024 | markets.businessinsider.com

Expert Ratings For OrthoPediatrics

May 7, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)

May 7, 2024 | finance.yahoo.com

OrthoPediatrics: Q1 Earnings Snapshot

See More Headlines

Receive KIDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/05/2024
Today: 9/07/2024
Next Earnings (Estimated): 11/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Medical Equipment
Current Symbol: NASDAQ:KIDS
CUSIP: N/A
CIK: 1425450
Web: www.orthopediatrics.com
Phone: (574) 268-6379
Fax: 574-269-3692
Employees: 200
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $43.50
High Stock Price Target: $52.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +41.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,970,000.00
Net Margins: -14.35%
Pretax Margin: -15.44%
Return on Equity: -5.44%
Return on Assets: -4.67%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 4.90
Quick Ratio: 1.96

Sales & Book Value

Annual Sales: $175.07 million
Price / Sales: 4.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.33 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 23,829,000
Free Float: 16,251,000
Market Cap: $730.60 million
Optionable: Optionable
Beta: 1.19

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Mark C. Throdahl (Age 73)
Executive Chairman
Mr. David R. Bailey (Age 45)
President, CEO & Director
Comp: $588.47k
Mr. Fred L. Hite (Age 56)
CFO, Principal Financial & Accounting Officer, COO and Director
Comp: $578.75k
Mr. Daniel J. Gerritzen (Age 54)
Executive VP of Legal & General Counsel
Comp: $470.44k
Mr. Gregory A. Odle (Age 54)
President of Scoliosis
Comp: $484.32k
Mr. Kevin L. Unger CHE (Age 52)
MBA/MSHA, President of Enabling Technologies
Comp: $56.25k
Mr. Joseph W. Hauser (Age 42)
President of Trauma & Deformity Correction
Comp: $470.44k
Mr. Joel Batts
Senior Vice President of Clinical & Regulatory Affairs
Mr. Mark Karshner
Senior Vice President of International Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KIDS Stock Analysis - Frequently Asked Questions

How have KIDS shares performed this year?: OrthoPediatrics' stock was trading at $32.51 at the start of the year. Since then, KIDS stock has decreased by 5.7% and is now trading at $30.66.
View the best growth stocks for 2024 here.
How were OrthoPediatrics' earnings last quarter?: OrthoPediatrics Corp. (NASDAQ:KIDS) released its quarterly earnings data on Monday, August, 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.08. The business had revenue of $52.80 million for the quarter, compared to analyst estimates of $52.40 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.44% and a negative net margin of 14.35%.
What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?: 15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did OrthoPediatrics IPO?: OrthoPediatrics (KIDS) raised $52 million in an IPO on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.
Who are OrthoPediatrics' major shareholders?: OrthoPediatrics' top institutional investors include Dimensional Fund Advisors LP (1.97%), Paradigm Capital Management Inc. NY (0.56%), Commonwealth Equity Services LLC (0.31%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include David R Bailey, Mark C Throdahl, Fred Hite, Gregory A Odle, Daniel J Gerritzen, Joseph W Hauser, Terry D Schlotterback, Harold Ruf, (Reynolds) Marie C Infante and Jennifer N Pritzker.
View institutional ownership trends.
How do I buy shares of OrthoPediatrics?: Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of OrthoPediatrics own?: Based on aggregate information from My MarketBeat watchlists, some other companies that OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and Cisco Systems (CSCO).